DNTH — Dianthus Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.17bn
- $3.28bn
- $2.04m
Magenta Therapeutics hits record low after blood cancer therapy trial raises safety concerns
Magenta down after blood cancer therapy trial shows adverse event in patients
Brief: Magenta Therapeutics Provides Update For Mgta-117 Phase 1/2 Dose Escalation Clinical Trial
U.S. STOCKS ON THE MOVE-Apparel stocks, copper and silver miners
U.S. STOCKS ON THE MOVE-Alphabet, Moderna, chip stocks
U.S. STOCKS ON THE MOVE-Eli Lilly, Payment firms, Big tech
U.S. STOCKS ON THE MOVE-Pinterest, PayPal, Magenta Therapeutics
Magenta Therapeutics surges on positive results in blood cancer therapy study
Brief: Magenta Therapeutics Presents Positive MGTA-117 Clinical Data At The American Society Of Hematology Annual Meeting, Provides Program Updates
Brief: Magenta Therapeutics Inc Reports Quarterly Net Loss Per Share Of $0.27
Magenta Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Magenta Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Magenta Therapeutics May Offer, Sell Shares Of Common Stock Of Up To $50 Million
Brief: Magenta Therapeutics appoints Michael Vasconcelles, M.D. to the board of directors
Brief: Magenta Therapeutics Reports Quarterly Loss Per Share $0.29
Brief: Magenta Therapeutics Files For Mixed Shelf Of Up To $250 Million
Magenta Therapeutics down on larger-than-expected Q1 loss
Magenta Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations From Mgta-117 Clinical Trial And Other Program Highlights